Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Seton Cancer Institute at Saint Mary's - Saginaw
1863
mi
from 98109
Saginaw, MI
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Seton Cancer Institute at Saint Mary's - Saginaw
1863
mi
from 98109
Saginaw, MI
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Munson Medical Center
1748
mi
from 98109
Traverse City, MI
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Munson Medical Center
1748
mi
from 98109
Traverse City, MI
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Fairview Ridges Hospital
1395
mi
from 98109
Burnsville, MN
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Fairview Ridges Hospital
1395
mi
from 98109
Burnsville, MN
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Mercy and Unity Cancer Center at Mercy Hospital
1385
mi
from 98109
Coon Rapids, MN
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Mercy and Unity Cancer Center at Mercy Hospital
1385
mi
from 98109
Coon Rapids, MN
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
CCOP - Duluth
1411
mi
from 98109
Duluth, MN
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
CCOP - Duluth
1411
mi
from 98109
Duluth, MN
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Miller - Dwan Medical Center
1411
mi
from 98109
Duluth, MN
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Miller - Dwan Medical Center
1411
mi
from 98109
Duluth, MN
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Fairview Southdale Hospital
1390
mi
from 98109
Edina, MN
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Fairview Southdale Hospital
1390
mi
from 98109
Edina, MN
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Mercy and Unity Cancer Center at Unity Hospital
1389
mi
from 98109
Fridley, MN
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Mercy and Unity Cancer Center at Unity Hospital
1389
mi
from 98109
Fridley, MN
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Hutchinson Area Health Care
1341
mi
from 98109
Hutchinson, MN
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Hutchinson Area Health Care
1341
mi
from 98109
Hutchinson, MN
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
HealthEast Cancer Care at St. John's Hospital
1402
mi
from 98109
Maplewood, MN
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
HealthEast Cancer Care at St. John's Hospital
1402
mi
from 98109
Maplewood, MN
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Minnesota Oncology - Maplewood
1402
mi
from 98109
Maplewood, MN
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Minnesota Oncology - Maplewood
1402
mi
from 98109
Maplewood, MN
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Hennepin County Medical Center - Minneapolis
1391
mi
from 98109
Minneapolis, MN
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Hennepin County Medical Center - Minneapolis
1391
mi
from 98109
Minneapolis, MN
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
1392
mi
from 98109
Minneapolis, MN
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
1392
mi
from 98109
Minneapolis, MN
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
New Ulm Medical Center
1350
mi
from 98109
New Ulm, MN
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
New Ulm Medical Center
1350
mi
from 98109
New Ulm, MN
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Humphrey Cancer Center at North Memorial Outpatient Center
1387
mi
from 98109
Robbinsdale, MN
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Humphrey Cancer Center at North Memorial Outpatient Center
1387
mi
from 98109
Robbinsdale, MN
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Mayo Clinic Cancer Center
1450
mi
from 98109
Rochester, MN
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Mayo Clinic Cancer Center
1450
mi
from 98109
Rochester, MN
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Park Nicollet Cancer Center
1388
mi
from 98109
Saint Louis Park, MN
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Park Nicollet Cancer Center
1388
mi
from 98109
Saint Louis Park, MN
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
United Hospital
1399
mi
from 98109
Saint Paul, MN
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
United Hospital
1399
mi
from 98109
Saint Paul, MN
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
St. Francis Cancer Center at St. Francis Medical Center
1383
mi
from 98109
Shakopee, MN
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
St. Francis Cancer Center at St. Francis Medical Center
1383
mi
from 98109
Shakopee, MN
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Lakeview Hospital
1410
mi
from 98109
Stillwater, MN
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Lakeview Hospital
1410
mi
from 98109
Stillwater, MN
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Ridgeview Medical Center
1370
mi
from 98109
Waconia, MN
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Ridgeview Medical Center
1370
mi
from 98109
Waconia, MN
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Willmar Cancer Center at Rice Memorial Hospital
1305
mi
from 98109
Willmar, MN
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Willmar Cancer Center at Rice Memorial Hospital
1305
mi
from 98109
Willmar, MN
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Minnesota Oncology - Woodbury
1407
mi
from 98109
Woodbury, MN
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Minnesota Oncology - Woodbury
1407
mi
from 98109
Woodbury, MN
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
University of Mississippi Cancer Clinic
1983
mi
from 98109
Jackson, MS
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
University of Mississippi Cancer Clinic
1983
mi
from 98109
Jackson, MS
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Heartland Hematology Oncology Associates, Incorporated
1499
mi
from 98109
Kansas City, MO
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Heartland Hematology Oncology Associates, Incorporated
1499
mi
from 98109
Kansas City, MO
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Research Medical Center
1508
mi
from 98109
Kansas City, MO
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Research Medical Center
1508
mi
from 98109
Kansas City, MO
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
North Kansas City Hospital
1502
mi
from 98109
Kansas City, MO
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
North Kansas City Hospital
1502
mi
from 98109
Kansas City, MO
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Saint Luke's East - Lee's Summit
1521
mi
from 98109
Lee's Summit, MO
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Saint Luke's East - Lee's Summit
1521
mi
from 98109
Lee's Summit, MO
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Heartland Regional Medical Center
1468
mi
from 98109
Saint Joseph, MO
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Heartland Regional Medical Center
1468
mi
from 98109
Saint Joseph, MO
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Saint Louis University Cancer Center
1718
mi
from 98109
Saint Louis, MO
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Saint Louis University Cancer Center
1718
mi
from 98109
Saint Louis, MO
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
St. Vincent Healthcare Cancer Care Services
668
mi
from 98109
Billings, MT
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
St. Vincent Healthcare Cancer Care Services
668
mi
from 98109
Billings, MT
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Hematology-Oncology Centers of the Northern Rockies - Billings
663
mi
from 98109
Billings, MT
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Hematology-Oncology Centers of the Northern Rockies - Billings
663
mi
from 98109
Billings, MT
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Bozeman Deaconess Cancer Center
553
mi
from 98109
Bozeman, MT
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Bozeman Deaconess Cancer Center
553
mi
from 98109
Bozeman, MT
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
St. James Healthcare Cancer Care
477
mi
from 98109
Butte, MT
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
St. James Healthcare Cancer Care
477
mi
from 98109
Butte, MT
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Sletten Cancer Institute at Benefis Healthcare
515
mi
from 98109
Great Falls, MT
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Sletten Cancer Institute at Benefis Healthcare
515
mi
from 98109
Great Falls, MT
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
St. Peter's Hospital
489
mi
from 98109
Helena, MT
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
St. Peter's Hospital
489
mi
from 98109
Helena, MT
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Kalispell Regional Medical Center
373
mi
from 98109
Kalispell, MT
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Kalispell Regional Medical Center
373
mi
from 98109
Kalispell, MT
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Glacier Oncology, PLLC
373
mi
from 98109
Kalispell, MT
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Glacier Oncology, PLLC
373
mi
from 98109
Kalispell, MT
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Kalispell Medical Oncology at KRMC
373
mi
from 98109
Kalispell, MT
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Kalispell Medical Oncology at KRMC
373
mi
from 98109
Kalispell, MT
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Montana Cancer Center
395
mi
from 98109
Missoula, MT
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Montana Cancer Center
395
mi
from 98109
Missoula, MT
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
1355
mi
from 98109
Omaha, NE
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
1355
mi
from 98109
Omaha, NE
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Cancer Institute of New Jersey at Cooper - Voorhees
2384
mi
from 98109
Voorhees, NJ
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Cancer Institute of New Jersey at Cooper - Voorhees
2384
mi
from 98109
Voorhees, NJ
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Monter Cancer Center of the North Shore-LIJ Health System
2414
mi
from 98109
Lake Success, NY
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Monter Cancer Center of the North Shore-LIJ Health System
2414
mi
from 98109
Lake Success, NY
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
CCOP - North Shore University Hospital
2414
mi
from 98109
Manhasset, NY
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
CCOP - North Shore University Hospital
2414
mi
from 98109
Manhasset, NY
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Don Monti Comprehensive Cancer Center at North Shore University Hospital
2413
mi
from 98109
Manhasset, NY
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Don Monti Comprehensive Cancer Center at North Shore University Hospital
2413
mi
from 98109
Manhasset, NY
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Long Island Jewish Medical Center
2416
mi
from 98109
New Hyde Park, NY
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Long Island Jewish Medical Center
2416
mi
from 98109
New Hyde Park, NY
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
SUNY Upstate Medical University Hospital
2233
mi
from 98109
Syracuse, NY
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
SUNY Upstate Medical University Hospital
2233
mi
from 98109
Syracuse, NY
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
2329
mi
from 98109
Chapel Hill, NC
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
2329
mi
from 98109
Chapel Hill, NC
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Kinston Medical Specialists
2429
mi
from 98109
Kinston, NC
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Kinston Medical Specialists
2429
mi
from 98109
Kinston, NC
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Rutherford Hospital
2223
mi
from 98109
Rutherfordton, NC
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Rutherford Hospital
2223
mi
from 98109
Rutherfordton, NC
Click here to add this to my saved trials